Autopsy report · NCT00798590

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

“PI left JHU”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 6 months before it stopped.
• 19 participants enrolled.
• Results were posted on the registry 6 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Johns Hopkins University

Sponsor type

University, hospital or other

Conditions

Critically Ill; Hypoglycemia

Interventions

Glucagon-Like Peptide-1; Saline

Participants

19

Sites

1

Countries

United States

Trials that died the same way

• Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination
  “PI left JHU and is not able to be reached for updates” (75% match in meaning)
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
  “PI left NIH.” (66% match in meaning)
• Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)
  “PI leaving NIH.” (64% match in meaning)
• Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure
  “Departure of PI” (63% match in meaning)
• Treatment of Chorioamnionitis After Delivery
  “PI retired” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.